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High residual carriage of vaccine-serotype
Streptococcus pneumoniae after introduction
of pneumococcal conjugate vaccine in Malawi
Todd D. Swarthout 1,2,3✉, Claudio Fronterre 4, José Lourenço 5, Uri Obolski 6,7, Andrea Gori2,
Naor Bar-Zeev 1,8, Dean Everett 1,9, Arox W. Kamng’ona 10, Thandie S. Mwalukomo11, Andrew A. Mataya1,
Charles Mwansambo12, Marjory Banda13, Sunetra Gupta5, Peter Diggle4, Neil French1,14,15 &
Robert S. Heyderman1,2,15
There are concerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Africa
sub-optimally interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and
transmission. Here we assess PCV carriage using rolling, prospective nasopharyngeal
carriage surveys between 2015 and 2018, 3.6–7.1 years after Malawi’s 2011 PCV13 intro-
duction. Carriage decay rate is analysed using non-linear regression. Despite evidence of
reduction in VT carriage over the study period, there is high persistent residual carriage.
This includes among PCV-vaccinated children 3–5-year-old (16.1% relative reduction from
19.9% to 16.7%); PCV-unvaccinated children 6–8-year-old (40.5% reduction from 26.4%
to 15.7%); HIV-infected adults 18-40-years-old on antiretroviral therapy (41.4% reduction
from 15.2% to 8.9%). VT carriage prevalence half-life is similar among PCV-vaccinated and
PCV-unvaccinated children (3.26 and 3.34 years, respectively). Compared with high-
income settings, there is high residual VT carriage 3.6–7.1 years after PCV introduction.
Rigorous evaluation of strategies to augment vaccine-induced control of carriage, including
alternative schedules and catch-up campaigns, is required.
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S treptococcus pneumoniae is estimated to be responsible forover 318,000 (uncertainty ratio: 207,000–395,000) deathsevery year in children aged 1–59 months worldwide, with
the highest mortality burden among African children1. S. pneu-
moniae has over 90 immunological serotypes and is a common
coloniser of the human nasopharynx, particularly in young
children, resource-poor and HIV-affected populations2. Although
most carriers are asymptomatic, pneumococcal colonisation is a
necessary prerequisite for transmission and the development of
disease, including pneumonia, meningitis, and septicaemia3.
In high-income country (HIC) settings (including Europe and
North America), routine infant administration of pneumococcal
conjugate vaccine (PCV) has rapidly reduced vaccine serotype
(VT) invasive pneumococcal disease (IPD)4–6 and carriage7–9.
Importantly, this has occurred in vaccinated and unvaccinated
age groups. Thus, indirect protection resulting from a reduction
in carriage and transmission amplifies PCV impact and cost-
effectiveness10. In HICs, PCV was commonly initiated soon after
becoming available in 2000, initially with 7-valent Prevenar®
(PCV7) usually with a booster dose in the second year of life in
addition to doses in infancy (e.g. 2+ 1 or 3+ 1), subsequently
switching to 10-valent Synflorix® (PCV10) or 13-valent Pre-
venar13® (PCV13). PCVs in Africa were predominately intro-
duced from 2011 as supportive funding became available
through the Global Alliance for Vaccines and Immunisation
(GAVI, the Vaccine Alliance). The schedules most often imple-
mented, with PCV10 or PCV13, were given in infancy without a
booster (3+ 0). South Africa, Rwanda, and The Gambia were the
exceptions, implementing PCV7 in 2009 and then PCV13. South
Africa has used a 2+ 1 schedule, with the third dose given at
9 months of age with the measles vaccine (See Supplementary
Table 1 for an overview of the regional differences in vaccine
schedules and formulations).
Pneumococcal epidemiology in sub-Saharan Africa (sSA) is
characterised by higher rates of carriage and transmission than
HIC settings11–15. Carriage studies pre-dating PCV introduction
in Kenya11, Mozambique12, Malawi13, The Gambia14, and South
Africa15, for example, reported pneumococcal carriage prevalence
values ranging from 59 to 90% among children < 5 years old, with
colonisation occurring rapidly early in life16. This differs mark-
edly from high-income settings including, for example, the UK17,
the USA18, and the Netherlands19, reporting pre-PCV pneumo-
coccal carriage prevalences of 48–68%.
Vaccine trials and post-routine-introduction studies in sSA
have demonstrated substantial direct effects of PCV against IPD,
pneumonia, and all-cause mortality among young children20–23.
Though PCV impact is not directly comparable between coun-
tries, and regions given differences in PCV implementation
strategies (formulations and schedules), these countries (e.g.,
Malawi [PCV13; 3+ 0]13, The Gambia [PCV7 and PCV13; 2+
1]20,21, Kenya [PCV10; 3+ 0]22, South Africa [PCV7 and PCV13;
2+ 1]23,24, and Mozambique [PCV13; 3+ 0]25,) have con-
sistently reported higher residual VT carriage than HICs (United
Kingdom [PCV7 and PCV13; 2+ 1]17, Netherlands [PCV7 and
PCV10; 3+ 1 and 2+ 1]26, USA [PCV7 and PCV13; 3+ 1]27).
See Supplementary Table 2 for an overview of regional differences
in residual VT carriage prevalence after the introduction of PCV
into routine Extended Programmes on Immunisation [EPIs]).
As reported for HIC settings17,27,28, there is also increasing
evidence of non-vaccine-serotype (NVT) carriage replacement in
sSA29,30. While NVT typically cause less invasive disease31, cap-
sule switching32 and genotypic shifts33 may lead to increases in
replacement. This is of particular concern in many sub-Saharan
African countries where the 3+ 0 schedule has been imple-
mented into infant EPIs34.
In November 2011, Malawi (previously PCV naïve) introduced
PCV13 as part of the national EPI, using a 3+ 0 schedule (6, 10,
and 14 weeks of age). A three-dose catch-up vaccination
campaign included infants < 1 year of age at the date of first
dose, receiving three doses at 1-month intervals. Previous field
studies in Malawi have reported high PCV13 uptake rates of
90–95%35,36, similar to the 92% PCV-3 coverage recently repor-
ted by WHO/UNICEF37. A 2015–2016 Malawian Ministry of
Health assessment reported a 12.8% HIV prevalence among adult
women (aged 15–64) and an HIV prevalence of 8.2% among
adult men38. In 2011, Malawi adopted Option B+, whereby all
HIV-infected pregnant or breastfeeding women commence life-
long full antiretroviral therapy (ART) regardless of clinical or
immunological stage, dramatically reducing mother-to-child
transmission39.
An earlier, small community-surveillance study in Karonga
District, northern Malawi, compared pneumococcal carriage
before and 2 years after PCV introduction13. VT carriage among
young PCV-vaccinated children (1–4 years of age) was 28.2%
before vs 16.5% after PCV introduction (Supplementary Table 5).
These data led us to hypothesise that despite evidence of PCV13
impact on IPD and pneumonia in Malawi40,41, in the longer term
after vaccine introduction there would be persistently high resi-
dual VT carriage and that this would maintain transmission in
both childhood and adult reservoirs. In this large population-
based study, we investigate this among children PCV13-
vaccinated through the routine EPI (in whom vaccine-induced
immunity begins to wane after the first year of life42); children too
old to have received PCV13; and HIV-infected adults on ART
who do not routinely receive pneumococcal vaccination but were
previously demonstrated to have a high carriage prevalence43,44.
We find that, despite evidence of reduction in VT carriage since
PCV13 introduction, there is high persistent residual carriage
among PCV-vaccinated and PCV-unvaccinated study popula-
tions. We show a VT carriage prevalence half-life that is similar
among older PCV-vaccinated and PCV-unvaccinated children.
These results, not dissimilar to a number of other sub-Saharan
African countries, underline the need for rigorous evaluation of
strategies to augment vaccine-induced control of carriage.
Results
Recruitment. Between 19 June 2015 and 6 December 2018, seven
rolling carriage surveys were completed: dates for each survey
were, respectively, (1) June to August 2015; (2) October 2015 to
April 2016; (3) May to October 2016; (4) November 2016 to April
2017; (5) May to October 2017; (6) November 2017 to June 2018;
(7) June to December 2018. This spanned a period of 3.6–7.1 years
after Malawi’s 12 November 2011 introduction of PCV. Given that
seasonality was found to be associated with pneumococcal carriage
in a previous study in Malawi16, enrolment was evenly distributed
across seasons of high and low carriage incidence.
Overall, 7554 individuals were screened (Fig. 1), including 371
infants 4–8 weeks old (prior to receiving the first dose PCV), 602
PCV-vaccinated children 18 weeks to 1 year old, 538 PCV-
vaccinated children 2 years old, 2696 PCV-vaccinated children
3–7 years old, 1505 PCV-unvaccinated children 3–10 years old,
and 1842 HIV-infected adults 18–40 years old and on ART
(PCV-unvaccinated). Among those screened, 24 (6.5%) infants,
196 (5.1%) children age-eligible for PCV, 96 (6.4%) children age-
ineligible for PCV, and 67 (3.6%) HIV-infected adults were
excluded (Fig. 1) from recruitment after screening. Twenty-three
participants (eighteen children, five HIV-infected adults) did not
allow a swab to be collected after recruitment. The final analysis
included 7148 participants: 346 infants recruited before receiving
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their first dose PCV, 566 children 18 weeks to 1 year old and PCV
vaccinated, 499 children 2 years old and PCV vaccinated, 2565
children 3–7 years and PCV vaccinated, 1402 children 3–10 years
old and PCV-unvaccinated, and 1770 HIV-infected adults on
ART and PCV-unvaccinated. Among school-goers, of the 3781
invitation letters sent home, 1493 (39.5%) resulted in a parent/
guardian visiting the school for further study information and
screening. The number of letters actually received by the parents/
guardians and the reasons for parents/guardians not accepting the
invitations were not routinely documented. During household
recruitment, study teams maintained a diary to record the
number of homes visited. An average of 7.2 households was
approached for every child screened. Reasons for failing to
screen-at-household included, (i) no one home, (ii) someone
home but no age-eligible child available, and (iii) age-eligible
child home but no parent/guardian available. Among the children
in the final analysis, 3605 were recruited from households and
1427 from schools.
Demographics and vaccination history. When assessing the
distribution of demographics in Table 1 to optimise the overlap in
ages, we restricted the analysis to children 3–7 years of age in each
PCV-unvaccinated and PCV-vaccinated children. Though the
surveyed groups had similar demographics, a higher proportion
of older PCV-unvaccinated children (recruited from schools)
lived in houses with some more costly infrastructure (walls of
burnt brick, a water toilet, a water tap to house); these children
also had a higher index of household possessions and a higher
crowding index. Among those screened and age-eligible for PCV
vaccination, 98.7% (3785/3836) reported receiving at least one
dose of PCV. Among the 3630 PCV-vaccinated children recruited
and providing a nasopharyngeal swab (NPS), 1209 (33.3%) had
documented (in the health passport) vaccination status with
vaccination dates; ranging from 86.5% among the youngest vac-
cinated age group (18 weeks to 1 year old) to 25.7% among the
oldest vaccinated age group (3–7 years old). Among those with
health passports confirming dates of vaccination, the median
(IQR) ages at first, second, and third dose of PCV were 6.3 (3.2),
11.2 (5.0), and 16.4 (8.1) weeks, respectively; 1143 (94.5%)
received three doses PCV, 24 (2.0%) only two doses, and 42
(3.5%) only one dose.
Pneumococcal carriage. Figure 2 reports the carriage dynamics
of S. pneumoniae per rolling survey, stratified by study group
(refer to Supplementary Tables 3 and 4 for VT and NVT pre-
valence data used for this figure). Using aggregated survey data,
VT and NVT carriage prevalence were, respectively, 8.4% (95%
confidence interval (CI) 5.7–11.8) and 33.8% (28.8–39.1)
among children 4–8 weeks (prior to first dose PCV; surveys
5–7); 17.1% (95% CI 14.2–20.5) and 62.7% (58.6–66.6) among
PCV-vaccinated children 18 weeks to 1 year old (surveys 4–7);
18.4% (95% CI 15.3–22.1) and 58.5% (54.1–62.8) among PCV-
vaccinated children 2 years old (surveys 4–7); 18.0% (95% CI
16.5–19.5) and 56.2% (54.2–58.1) among PCV-vaccinated
children 3–7 years old (surveys 1–7); 18.2% (95% CI
16.2–20.3) and 38.5% (35.9–41.0) among PCV-unvaccinated
children 3–10 years old (surveys 1–7); and 12.3% (95% CI
10.8–13.9) and 28.1% (26.0–30.2) among HIV-infected adults
on ART (surveys 1–7).
A sensitivity analysis among PCV-vaccinated age groups
showed that neither the overall VT prevalence nor the VT
distribution changed significantly when limiting these analyses to
children (i) who received only one, only two, or all three doses
PCV; (ii) with document-confirmed PCV vaccination, or (iii) who
adhered to the vaccination schedule to within 2 weeks of each
scheduled dose. As shown in Supplementary Fig. 1, when
stratified by age (in years) and aggregating survey data, reduction
in VT carriage was not exponential among vaccinated children.
VT carriage increased slightly during the first 4 years of life, from
16.6% (95% CI 11.9–22.6) among children 18 weeks to 11 months
old to 17.4% (13.6–21.7), 18.6% (15.1–22.1), and 19.5%
(17.3–22.1) among 1-, 2-, and 3-year-old children, respectively.
VT carriage then decreased to 18.5% (16.0–20.9), 14.4%
(10.8–19.0), 12.0% (6.7–19.3), and 7.0% (1.4–17.1) among 4-,
5-, 6-, and 7 years old, respectively.
Although all 13 VTs were identified in each of the three older
(3–40 years old) study groups, with serotype 3 the predominant
VT in each, serotype carriage dynamics were more heterogenous
among those <3 years old (Fig. 3). Serotype 1, a common cause of
IPD in Africa45,46, contributed 3.0% to the all-ages VT carriage
prevalence. Supplementary Tables 7 and 8 show the proportion of
total VT carriage attributed to individual VTs, stratified by study
group and survey among PCV-vaccinated and PCV-unvaccinated
study groups, respectively.
34 ineligible
• 4: HIV infected
• 9: receiving antibiotics
• 11: not PCV vaccinated
• 10: consent not provided
Infants 4–8 weeks
PCV13 unvaccinated
Children 18 weeks – 1 year
PCV13 vaccinated
Children 2 years
PCV13 vaccinated
Children 3–7 years
PCV13 vaccinated
Children 3–10 years
PCV13 unvaccinated
Adults 18–40 years, HIV-infected
Receiving ART, PCV13 unvaccinated
371 screened 602 screened 538 screened 2696 screened 1505 screened 1842 screened
24 ineligible
• 3: receiving antibiotics
• 21: consent not provided
38 ineligible
• 6: HIV infected
• 1: TB treatment
• 16: not PCV vaccinated
• 9: receiving antibiotics
• 6: consent not provided
96 ineligible
• 22 HIV infected
• 12: TB treatment
• 21: receiving antibiotics
• 19: consent not provided
• 22: assent not provided
67 ineligible
• 9: TB treatment
• 33: age-ineligible
• 5: terminal illness
• 6: not receiving ART
• 14: consent not provided
347 recruited & completed CRF 568 recruited & completed CRF 500 recruited & completed CRF 2572 recruited & completed CRF 1409 recruited & completed CRF 1775 recruited & completed CRF
124 ineligible
• 19: HIV infected
• 6: TB treatment
• 24: not PCV vaccinated
• 41: receiving antibiotics
• 34: consent not provided
1: swab not provided after
recruitment
1: swab not provided after
recruitment
7: swab not provided after
recruitment
7: swab not provided after
recruitment
5: swab not provided after
recruitment
2: swab not provided after
recruitment
346 in final analysis 566 in final analysis 499 in final analysis 2565 in final analysis 1402 in final analysis 1770 in final analysis
Fig. 1 Recruitment flow diagram. Among school-goers (6–10 years old), the number reported as screened does not include parents/guardians who did not
come to the school after written invitation. Overall, 3781 letters of invitation were sent to parents/guardians during recruitment of school-goers. Of these,
1493 (39.5%) came to the school to be further informed of the study and consider their child’s participation. Reasons for not accepting the invitation were
not routinely collected. A total 1427 school-goers were recruited. Among children recruited from household (18 weeks to 5 years old), study teams
maintained a diary of number of homes visited (i.e. knocked on gate/door of main house). An average of 7.2 household were approached for every child
screened. Reasons for failing to screen-at-household included, (i) no one home, (ii) someone home but no age-eligible child home, and (iii) age-eligible
child home but no parent/guardian available.
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Change in carriage prevalence over time. To minimise con-
founding, we calculated relative change in carriage prevalence and
prevalence ratios on a narrower age range within each study
group (Table 2). Among children 3–5 years old (PCV vaccinated),
aggregated (surveys 1–7) VT and NVT carriage prevalence were,
respectively, 18.5% (95% CI 16.9–20.1) and 57.2% (55.2–59.2).
There was a 16.1% relative reduction in VT carriage, from 19.9%
(15.7–25.0) in survey 1 to 16.7% (13.0–21.1) in survey 7. There
was a 2.0% relative decrease in NVT carriage, from 64.3%
(58.6–69.7) to 63.0% (57.6–68.1). When adjusted for age (years
old) at recruitment, the adjusted prevalence ratio (aPR) over the
3.5-year study was 0.919 (0.845–0.999) p= 0.047 for VT carriage
and 0.978 (0.944–1.013) p= 0.208 for NVT carriage. Among
children 6–8 years old (PCV-unvaccinated), aggregated (surveys
1–7) VT and NVT carriage prevalence were, respectively, 18.4%
(95% CI 15.6–21.5) and 39.6% (35.9–43.3). There was a 40.5%
relative reduction in VT carriage, from 26.4% (18.3–36.4) in
survey 1 to 15.7% (8.9–26.3) in survey 7. There was a 12.3%
Table 1 Demographic and household characteristics of study participants.
4–8 wks old
PCV-unvacc’d
(n = 346)
18 wks–1 yr old
PCV-vacc’d
(n = 566)
2 yrs old
PCV-vacc’d
(n = 499)
3–7 yrs old
PCV-vacc’d
(n = 2565)
3–10 yrs old
PCV-unvacc’d
(n = 1402)
18–40 yrs old HIV-
infected on ART
PCV-unvacc’d
(n = 1770)
Demographics
Age yrs, median, (SD)
[range]
0.13 (0.018)
[0.08–0.17]
1.19 (0.46)
[0.35–1.99]
2.50 (0.28)
[2.0–2.99]
4.14 (0.95)
[3.0–7.9]
8.49 (1.63)
[3.6–10.99]
33.55 (5.83)
[18.0–40.9]
Gender, male n (%) 179 (51.7) 296 (52.3) 244 (48.9) 1271 (49.6) 718 (51.2) 559 (31.96)c
PCV received n (%)a,b
1 dose only — 1 (02) 0 26 (1.2) — —
2 doses only 7 (1.2) 1 (0.2) 19 (0.9)
3 doses 558 (98.6) 498 (99.8) 2051 (97.9)
Household crowdingd
Crowding index, mean
(median)e
2.5 (2.3) 2.6 (2.5) 2.5 (2.3) 2.6 (2.5) 2.9 (2.5) 2.1 (2.0)
Children < 5 yrs in HHe
Median [range] 1 [1–3] 1 [1–3] 1 [1–2] 1 [1–3] 1 [1–3] 0 [0–4]
Smoker in householdf,g
Yes, n (%) 28 (8.1) 41 (7.2) 43 (8.6) 124 (7.7)g 61/674 (9.1) 33/1092 (3.0)
House structuref, n (%)
Wallse
Burnt brick/concrete 174 (50.4) 168 (29.6) 169 (33.9) 941 (36.7) 901 (64.3) 1212 (68.5)
Unburnt brick 166 (48.1) 397 (70.2) 330 (66.1) 1621 (63.2) 488 (34.8) 292 (16.5)
Mud, thick/thin 6 (1.5) 1 (0.2) 0 3 (0.10) 13 (0.9) 266 (15.0)
Floor
Tiles 1 (0.3) 1 (0.2) 0 3 (0.1) 4 (0.3) 20 (1.1)
Concrete 325 (93.9) 447 (89.9) 406 (89.2) 2125 (87.3) 1257 (91.9) 1619 (91.5)
Mud 20 (5.8) 48 (9.9) 49 (10.8) 307 (12.6) 107 (7.8) 130 (7.4)
Latrinee
Water toilet 16 (4.3) 13 (2.6) 11 (2.4) 57 (2.4) 238 (17.4) 279 (15.8)
Simple pit latrine 330 (95.7) 480 (97.0) 441 (97.6) 2368 (97.5) 1126 (82.4) 2 (0.1)
Other 0 2 (0.4) 0 2 (0.1) 3 (0.2) 1484 (84.1)
Watere
Tap to house 48 (13.9) 42 (8.5) 39 (8.6) 242 (9.9) 425 (31.1) 591 (33.4)
Communal tap 293 (84.9) 448 (90.1) 414 (91.0) 2156 (88.6) 884 (64.6) 947 (53.5)
Bore hole 3 (0.9) 7 (1.4) 2 (0.4) 30 (1.2) 45 (3.3) 181 (10.2)
Well (covered/open) 2 (0.3) 0 0 7 (0.3) 14 (1.0) 50 (2.8)
Electricity at household
Yes 274 (79.4) 379 (76.3) 342 (75.2) 1742 (71.5) 1021 (74.6) 1275 (72.1)
Possessions indexh
mean (SD)e
7.1 (2.7) 6.4 (3.5) 6.4 (3.4) 6.8 (3.3) 8.2 (3.2) 8.2 (3.3)
Recruitment location: Infants 4–8 weeks were recruited from household or health centre (present for EPI); PCV-vaccinated children 18 weeks to 5 years old were recruited from household; PCV-
unvaccinated children 5–10 years old were recruited from schools; HIV-infected adults on ART were recruited from Queen Elizabeth Central Hospital ART Clinic.
PCV pneumococcal conjugate vaccine, ART antiretroviral therapy, SD standard deviation, wk week, yr year, vacc’d vaccinated, HH household.
aAmong subset of PCV-vaccinated children with written evidence of vaccination.
bn= 2096 among children 3–7 yrs old.
cThe gender distribution among HIV-infected adults recruited from ART Clinic is representative of the gender distribution among those attending the clinic.
dCrowding index: Calculated as number of household residents divided by number of bedrooms in main house; data only collected starting survey four.
eDistribution of these covariates was statistically significant when comparing unvaccinated children 3–7 years of age and vaccinated children 3–7 years of age. Crowding index (mean 2.9 vs 2.6,
respectively) p < 0.000; number of children < 5 yrs old in household (mean 0.7–1.1) p < 0.000; Walls of burnt bricks or concrete (61.5 vs 36.7) p < 0.000; Latrine, water toilet (17.4 vs 2.4) p < 0.000;
Water tap to house (31.1 vs 9.5) p < 0.000; Possession index (7.8 vs 6.8) p < 0.000.
fSmoker in household: the percentage of households with at least one household member who smokes tobacco; data only collected starting survey four. Ranking of household structure variables: each
variable is presented with the most costly category at top and least costly at bottom of list.
gn= 1615 among children 3–7 yrs old.
hPossession index: calculated as a sum of positive responses for household ownership of each of one of fifteen different functioning items: watch, radio, bank account, iron (charcoal), sewing machine
(electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television.
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relative increase in NVT carriage, from 40.7% (31.0–51.1) to
45.7% (34.4–57.5). When adjusted for age at recruitment, the aPR
over the 3.5-year study was 0.919 (0.845–0.999) p= 0.047 for VT
carriage and 0.978 (0.944–1.013) p= 0.208 for NVT carriage.
Among HIV-infected adults on ART (PCV-unvaccinated),
aggregated (surveys 1–7) VT and NVT carriage prevalence were,
respectively, 12.3% (95% CI 10.8–13.9) and 28.1% (26.0–30.2).
There was a 41.4% relative reduction in VT carriage, from 15.2%
(10.8–20.9) in survey 1 to 8.9% (5.7–13.7) in survey 7. There was
a 22.7% relative increase in NVT carriage, from 24.2% (18.8–30.7)
to 29.7% (23.8–36.4). When adjusted for age at recruitment, the
aPR over the 3.5-year study was 0.831 (0.735–0.938) p= 0.003 for
VT carriage and 0.963 (0.895–1.036) p= 0.307 for NVT carriage.
To further assess for potential confounders, we investigated
whether the demographic characteristics, as reported in Table 1,
have changed over the study period. Although there was change
in some covariates (Crowding index, Smoker in household,
Latrine type, Electricity at household, and Possessions index), the
magnitude was limited and, when adjusted for in the model, they
made no meaningful difference to the relationship between VT
carriage and time.
Contribution of serotype 3 to change in carriage prevalence.
Several post-PCV13 introduction studies have reported that
PCV13 is less immunogenic for serotype 3 compared with other
VTs47,48, We have therefore assessed this potential bias by clas-
sifying serotype 3 as an NVT in a separate analysis (Supple-
mentary Table 9). The aPRs for VT carriage prevalence among
PCV-vaccinated children 3–5 years of age followed the same
trend but was no longer statistically significant (aPR 0.919 [95%
CI 0.845, 0.999] p= 0.047 for analysis including serotype 3 as VT
vs aPR 0.942 [95% CI 0.856, 1.036] p= 0.218 for analysis
including serotype 3 as NVT).
Probability of VT carriage with age and carriage half-life.
Using non-linear regression analysis, with carriage data censored
below 3.6 years of age, to investigate the individual probability of
VT carriage as a function of a child’s age (years), the probability
of VT carriage declined with age for both vaccinated and
unvaccinated children (Fig. 4). However, the population-averaged
effect of not receiving PCV more than doubled an individual’s
probability of VT carriage at 3.6 years of age, β= 2.15 (95%
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Fig. 2 S. pneumoniae carriage prevalence per survey, stratified by study group. Surveys 1–7 spanned a time of 3.6–7.1 years after the 12 November 2011
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CI 1.47–2.83) (Fig. 4 and Table 3). While reporting different
estimated probabilities of VT carriage at the individual level (e.g.
0.22 for PCV-vaccinated and 0.47 [α*β] for PCV-unvaccinated
children at 3.6 years of age), the estimated population-level half-
life (derived from individual carriage probability data) of VT
carriage prevalence was similar (T½: 3.34 years [1.78–6.26] vs T½:
3.26 years [2.42–4.38], respectively). Investigating probability of
NVT carriage, β was 0.91 (0.73–1.09), with similar estimated
probabilities of NVT carriage for individual vaccinated and
unvaccinated children at 3.6 years of age (0.59 and 0.54, respec-
tively [α*β]). The estimated half-life of NVT carriage prevalence
was also similar among PCV-vaccinated children (T½: 9.46 years
[4.69–19.04]) and PCV-unvaccinated (T½: 9.83 years
[5.69–16.99]). Assessment of the goodness-of-fit indicates a good
fit, with no discernible relationship between the residual and the
predicted values and the range of residuals compatible with the
theoretical mean and the standard deviations of 0 and 1,
respectively (Supplementary Fig. 3).
Discussion
In this population-based assessment of pneumococcal carriage we
surveyed potential reservoir populations from 3.6 to 7.1 years
after the introduction of routine PCV13 in Malawi. At the start of
the study, we found high VT carriage in all age groups, including
younger PCV-vaccinated children, older PCV-unvaccinated
children and HIV-infected adults on ART. Despite a statistically
significant relative reduction in VT prevalence over the next 3.5
years, residual carriage is higher than reported in high-income
settings (Supplementary Table 2). All 13 VTs were isolated
despite high vaccine uptake and good schedule adherence. There
was no significant change in NVT carriage prevalence. The 18.7%
residual VT carriage prevalence we report among PCV-
vaccinated children 1–4 years old was consistent with the 16.5%
reported in northern Malawi by Heinsbroek et al.13 for 2014
(Supplementary Table 5). Though the residual VT carriage pre-
valence we report for Blantyre was lower than that observed by
Heinsbroek et al. before vaccine introduction (28%)13, and may
have missed the greatest fall in VT prevalence soon after PCV
introduction, we did not observe the substantially lower levels
rapidly achieved in high-income low carriage prevalence settings
(<5%) associated with control of carriage and transmission17,26,27.
When aggregating surveys, reduction in VT carriage among PCV-
vaccinated children did not conform to a simple exponential
distribution, with a non-statistically significant increase among
children under 4 years of age, before evidence of a decrease
among older vaccinated children (Supplementary Fig. 1). In the
light of the recent WHO Technical Expert Consultation Report
on Optimisation of PCV Impact49, these data start to address the
paucity of information on the long-term impact of the widely
implemented 3+ 0 vaccine schedules on serotype-specific disease
and carriage in this region.
Despite the reporting of high residual VT carriage, our non-
linear statistical analysis shows a lower probability of VT carriage
among vaccinated children, starting at 3.6 years of age when the
model is censored. From this we speculate that vaccine-induced
protection, despite evidence of early waning of immunity (per-
haps within the first 6–12 months of life)42,50, does provide a
longer-term benefit to this population in providing a lower VT
carriage setpoint at an age when naturally acquired and herd
immunity begins to play a role in carriage control. A lower car-
riage setpoint among vaccinated children is of benefit in both
direct protection and in reducing transmission. We propose that
a comparable VT half-life at 3.6 years of age is due to a limited
role of vaccine-induced immunity that started to wane within the
first 12 months of life. The mechanism underlying the vaccine
effect could be prevention of carriage (reduced incidence) or
shortening of carriage duration (reduced point prevalence). There
is also evidence that, in older vaccinated and unvaccinated chil-
dren, the reductions in carriage prevalence are due to the indirect
benefits of vaccination augmented by naturally acquired immu-
nity to subcapsular protein antigens51,52.
These indirect benefits augmented by naturally acquired
immunity explains, in part, the more pronounced decline in VT
carriage among PCV-unvaccinated children 6–8 years old
(40.5%) and HIV-infected adults on ART (41.4%), compared with
younger vaccinated children 3–5 years old (16.1%; Table 2).
Using a dynamic transmission model fitted to data from this
population in Blantyre, Malawi, we have shown that the force of
infection (FOI; the rate by which a certain age group of suscep-
tible individuals is infected) is characterised by different trans-
mission potentials within and between age groups53. This analysis
suggests that the time period of the fastest FOI reduction for the
0–5 years old was between vaccine introduction and 2015 (when
no carriage data were collected), which contrasted with the older
age groups, for which the period of the fastest FOI reduction was
predicted to be just before or during the first three surveys.
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To achieve herd protection in settings with high carriage pre-
valence, such as Malawi, we need to effectively interrupt person-
to-person transmission. In Finland, a microsimulation model
suggested a moderate transmission potential of pneumococcal
carriage, predicting the elimination of VT carriage among those
vaccinated within 5–10 years of PCV introduction, assuming high
(90%) vaccine coverage and moderate (50%) vaccine efficacy
against acquisition54. Thus, vaccine impact predicted by trans-
mission models from low carriage prevalence settings probably
does not translate to high carriage prevalence settings. Although it
has previously been assumed that PCVs would eliminate VT
carriage in mature PCV programmes55, our data bring into
question the potential for either a sustained direct or indirect
effect on carriage using a 3+ 0 strategy. Alternative vaccine
schedules including those with a booster, should be evaluated to
determine whether a higher rate of vaccine-induced VT carriage
decay can be achieved.
In Malawi, the vaccine impact on carriage prevalence has been
less than that observed in Kenya, The Gambia and South Africa
which have used different vaccination strategies. Kenya reported a
reduction from 34 to 9% VT carriage among PCV-vaccinated
children under 5 years of age, 6 years after introduction of
10-valent PCV22. The Gambia reported a reduction from 50% to
13% VT carriage among children 2–5 years old, 20 months after
Table 2 Carriage prevalence among children and adults.
Children 3-5 years PCV-
vaccinated
% (n); 95% CI
Children 6-8 years PCV-
unvaccinated % (n); 95% CI
Adult, HIV-infected on ART PCV-
unvaccinated % (n); 95% CI
Survey 1 n = 286 n = 91 n = 198
Total carriage 84.2 (241) 79.5, 88.3 67.1 (61) 56.4, 76.5 39.4 (78)
VT 19.9 (57); 15,7, 25.0 26.4 (24) 18.3, 36.4 15.2 (30) 10.8–20.9
NVT 64.3 (184); 58.6, 69.7 40.7 (37) 31.0, 51.1 24.2 (48) 18.8–30.7
Survey 2 n = 303 n = 111 n = 201
Total carriage 76.0 (230) 70.7, 80.6 65.7 (73) 56.2, 74.5 47.2 (95)
VT 20.5 (62) 16.3, 25.4 21.6 (24) 14.9, 30.3 14.4 (29) 10.2–20.0
NVT 55.5 (168) 49.8, 61.0 44.1 (49) 35.2, 53.5 32.8 (66) 26.7–39.6
Survey 3 n = 361 n = 139 n = 279
Total carriage 78.1 (282) 73.5, 82.3 63.3 (88) 54.7, 71.3 44.5 (124)
VT 20.8 (75) 16.9, 25.3 21.6 (30) 15.5, 29.2 14.0 (39) 10.4–18.6
NVT 57.3 (207) 52.2, 62.4 41.7 (58) 33.8, 50.1 30.5 (85) 25.3–36.1
Survey 4 n = 378 n = 128 n = 308
Total carriage 67.0 (253) 61.9, 71.7 42.9 (55) 34.3, 52.0 42.9 (132)
VT 17.5 (66) 14.0, 21.6 14.8 (19) 9.6, 22.2 14.3 (44) 10.8–18.9
NVT 49.5 (187) 44.4, 54.5 28.1 (36) 21.0, 36.6 28.6 (88) 23.8–33.9
Survey 5 n = 371 n = 56 n = 305
Total carriage 80.6 (299) 76.2, 84.5 55.3 (31) 41.5, 68.7 38.4 (117)
VT 19.4 (72) 15.7, 23.8 8.9 (5) 3.7, 19.9 10.5 (32) 7.5–14.5
NVT 61.2 (227) 56.1, 66.0 46.4 (26) 33.8, 59.6 27.9 (85) 23.1–33.2
Survey 6 n = 382 n = 100 n = 277
Total carriage 67.3 (257) 62.3, 72.0 52.0 (52) 41.8, 62.1 32.5 (90)
VT 15.2 (58) 11.9, 19.2 15.0 (15) 9.2, 23.5 9.0 (25) 6.2–13.0
NVT 52.1 (199) 47.1, 57.1 37.0 (37) 28.1, 46.9 23.5 (65) 18.8–28.8
Survey 7 n = 324 n = 70 n = 202
Total carriage 79.7 (258) 74.8, 83.9 61.4 (43) 49.0, 72.8 38.6 (78)
VT 16.7 (54) 13.0, 21.1 15.7 (11) 8.9, 26.3 8.9 (18) 5.7–13.7
NVT 63.0 (204) 57.6, 68.1 45.7 (32) 34.4, 57.5 29.7 (60) 23.8–36.4
Total
(Survey 1-7)
n = 2405 n = 695 n = 1770
Total carriage 75.7 (1820) 73.9, 77.4 58.0 (403) 54.2, 61.7 40.4 (714)
VT 18.5 (444) 16.9, .20.1 18.4 (128) 15.6, 21.5 12.3 (217) 10.8–13.9
NVT 57.2 (1376) 55.2, 59.2 39.6 (275) 35.9, 43.3 28.1 (497) 26.0–30.2
cPRa (95% CI) p-value cPRa (95% CI) p-value cPRa (95% CI) p-value
Total carriage — — —
VT 0.912 (0.840, 0.990) 0.028 0.806 (0.690, 0.942) 0.007 0.847 (0.750, 0.957) 0.008
NVT 0.972 (0.939, 1.007) 0.112 0.964 (0.881, 1.056) 0.437 0.967 (0.899, 1.040) 0.362
aPRa (95% CI) p-value aPRa (95% CI) p-value aPRa (95% CI) p-value
Total carriage — — —
VT 0.912 (0.840, 0.990) 0.028 0.839 (0.712, 0.990) 0.037 0.831 (0.735, 0.938) 0.003
NVT 0.972 (0.939, 1.007) 0.112 0.974 (0.886 1.070) 0.583 0.963 (0.895, 1.036) 0.307
Relative changeb Relative changeb Relative changeb
Total carriage — — —
VT −16.1% −40.5% −41.4%
NVT −2.0% +12.3% 22.7%
Surveys 1–7 spanned a time of 3.6–7.1 years after Malawi’s November 2011 introduction of PCV.
cPR crude prevalence ratio, aPR adjusted prevalence ratio (adjusted for age [years old] at recruitment), CI confidence interval, VT vaccine serotype, NVT non-vaccine serotype, ART antiretroviral therapy.
aCarriage prevalence ratios (crude and adjusted) were calculated over the study duration of seven surveys by log-binomial regression using years (365.25 days) between date of Malawi’s PCV
introduction and participant recruitment, coded as a single time variable, allowing an estimate of (adjusted) prevalence ratio per annum.
bRelative change= [(VT prevalence of final survey−VT prevalence of initial survey)/VT prevalence of initial survey] × 100%.
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introducing the 7-valent PCV56. Likewise, a study from South
Africa showed reduced PCV13-serotype colonisation from 37% to
13% within 1 year of transitioning from PCV7 to PCV1357.
However, these countries have also not achieved the low carriage
prevalence seen in Europe and North America 2–3 years post
introduction4,18. As presented by Lourenço et al.53, we propose
that a high FOI in settings such as Malawi limits a 3+ 0 schedule
to achieving only a short duration of VT carriage control in
infants. While a 2+ 1 schedule, as deployed in South Africa, may
improve colonisation control, this remains unproven in other
African settings. Given the likely importance of an early reduction
in transmission intensity to maintain a reduced carriage pre-
valence, a catch-up-campaign with booster doses over a broader
age range (i.e. <5 years of age) may also be required. Although
GAVI has considerably reduced PCV costs for low-income
countries58,59, vaccine impact must be optimised (particularly
indirect effects) to achieve financial sustainability. The FOI and
determinants of transmission between and within age groups
need to be considered, as new approaches to improving vaccine-
induced carriage reduction are proposed and tested.
Unlike low-transmission settings60, as well as The Gambia29
and South Africa57, we observed a very modest decrease in NVT
carriage among young PCV-vaccinated children in Malawi. Given
evidence elsewhere of rapid serotype replacement after PCV
introduction, it is possible that serotype replacement and redis-
tribution had already occurred before the start of this study, and
that as part of a stochastic secular trend, we are now observing an
overall decrease in pneumococcal carriage prevalence. There may
have also been individual NVTs that increased, while other NVTs
decreased in prevalence. Though distribution of individual NVTs
warrant further analysis, our latex serotyping methods did not
allow for identifying individual NVT serotypes. It is also plausible
that overall improvement in living conditions (improved nutri-
tion, sanitation, and disease control) and health care (anti-
retroviral roll-out and rotavirus vaccination) have resulted in an
overall sustained drop in pneumococcal carriage as a result of
improved health, evidenced by falling under 5 mortality in recent
years61. Either way, the importance of this in NVT carriage will
become clearer as the trends in NVT invasive disease become
available from these different settings.
We have previously shown incomplete pneumococcal protein
antigen-specific reconstitution of natural immunity and high
levels of pneumococcal colonisation in HIV-infected Malawian
adults on ART43,44. While reporting here a significant decline
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Fig. 4 Modelling the relationship between a child’s probability of VT carriage and age. Estimated probabilities and pointwise 95% confidence intervals
(shaded regions) of the probability of an individual child’s vaccine-serotype (VT) carriage as a function of a child’s age (years), for an unvaccinated child
(red line) and a vaccinated child (blue line). The fitted line for unvaccinated children includes the range of the empiric data. The fitted line for vaccinated
children is left censored at 3.6 years old and extrapolated beyond the oldest vaccinated child (7.9 years old). The model shows significantly different
estimated probabilities of VT carriage for an individual (distance between lines), while the estimated population-level half-life of VT carriage (derived from
individual carriage probability data; refer to Table 3 in manuscript) translates to very similar estimates among PCV-vaccinated (3.34 years) and
PCV-unvaccinated (3.26 years) children.
Table 3 Estimates for probability of carriage with age and carriage half-life.
Parameter VT NVT
Estimate 95% CI Estimate 95% CI
Carriage prevalence at censoring age (3.6 years) for vaccinated children (α) 0.22 0.19, 0.25 0.59 0.55, 0.63
Carriage prevalence at censoring age (3.6 years) for unvaccinated children (α*β) 0.47 0.33, 0.60 0.54 0.43, 0.64
Decay rate of carriage prevalence with age for vaccinated children (δv) 0.21 0.11, 0.39 0.07 0.04, 0.15
Carriage half-life for vaccinated children (log (2)/δv) 3.34 1.78, 6.26 9.46 4.69, 19.04
Decay rate of carriage prevalence with age for unvaccinated children (δu) 0.21 0.16, 0.29 0.07 0.04, 0.12
Carriage half-life for unvaccinated children (log (2)/δu) 3.26 2.42, 4.38 9.83 5.69, 16.99
Effect of not receiving PCV (β) 2.15 1.47, 2.83 0.91 0.73, 1.09
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(41.4% relative reduction, Table 2) in VT carriage among an
HIV-infected adult population suggests some indirect benefit in
this population following routine infant PVC13 introduction, the
residual 8.9% VT carriage may represent a persistent reservoir of
VT carriage and transmission. Previous studies in Malawi and
South Africa have suggested that despite a higher risk of VT
pneumococcal colonisation among HIV-infected women, they are
still unlikely to be a significant source of transmission to their
children24. However, in the context of routine infant PCV13 and
persistent pneumococcal carriage, the balance of transmission
may now be different. Given the higher risk of IPD, ongoing
burden of pneumococcal pneumonia62, and the evidence that
PCV protects HIV-infected adults from recurrent VT pneumo-
coccal infections63, targeted vaccination benefitting this at-risk
population may help reduce overall carriage and disease
prevalence.
Though this work provides a robust community-based estimate
of VT and NVT pneumococcal carriage in Blantyre, there are
some limitations worth noting. The study was conducted over a
relatively short timeframe for understanding long-term temporal
trends. For this reason, the statistical analysis has some limita-
tions in its ability to disentangle the effects of calendar time and
age since vaccination, given the small overlap in ages of vacci-
nated and unvaccinated children in our data (Supplementary
Fig. 2). It is also possible that re-adjustment of carriage dynamics
(VT and NVT prevalence as well as serotype-specific trends) have
already occurred between PCV introduction and our first carriage
survey. As reported elsewhere64,65, a major challenge in field-
based surveillance studies is ascertainment of vaccine coverage.
Measurement of vaccination status depends predominantly on
health passport with limited capacity for verification of either
recorded or reported vaccination status. However, reported high
coverage is concordant to that reported by other studies in
Malawi and any misclassification is therefore likely to be small
and would not significantly change the findings. Jahn et al.65
showed that Bacillus Calmette–Guerin (BCG) scar data allow
inference of population vaccination coverage independently from
vaccination records, reporting a similar prevalence of BCG scar
among children < 5 years with no health passport compared with
those with a health passport and BCG reported (70% vs 78%,
respectively). Subsequently, a 2015 Malawi cluster vaccination
coverage survey reported that 94% of children 12–23 months of
age had a BCG scar36. Although there are pre-vaccine-
introduction data from elsewhere in Malawi, there are no
equivalent historical carriage data for urban settings in Malawi
using the same sampling frame. However, this does not detract
from the finding of high levels of residual VT carriage in these
reservoir populations. Finally, given evidence that more sensitive
serotyping methods that detect multiple serotype carriage (e.g. by
DNA microarray)66,67 will increase VT carriage estimates, our
carriage prevalence data likely underestimate the true residual
VT, as well NVT, prevalence levels.
In conclusion, despite success in achieving direct protection of
infants against disease, a 3+ 0 PCV13 schedule in Malawi has not
achieved the low universal VT carriage prevalence reported in
high-income settings and that is required to control carriage and
transmission. We propose that although vaccine-induced
immunity reduces the risk of VT carriage in children, in the
context of a high residual FOI, this impact is limited by rapid
waning (perhaps within the first 6-12 months of life) of vaccine-
induced mucosal immunity and pneumococcal recolonisation.
Therefore, alternative schedules and vaccine introduction
approaches in high pneumococcal carriage, high-disease-burden
countries should be revisited through robust evaluation rather
than through programmatic change without supporting evidence.
Furthermore, we need to better understand the relative impact of
waning vaccine-induced immunity, indirect vaccine protection
and naturally acquired immunity on VT carriage in 2–3 years
after vaccination.
Methods
Study design. This was a prospective observational study using stratified random
sampling to measure pneumococcal nasopharyngeal carriage in Blantyre, Malawi.
Sampling consisted of twice-annual rolling cross-sectional surveys over 3.5 years.
Study population. Blantyre is located in southern Malawi and has an urban
population of ~1.3 million. Recruitment included four groups: (i) healthy infants
4–8 weeks old prior to the first dose of PCV, recruited from vaccination centres
using systematic sampling; (ii) randomly sampled healthy children 18 weeks to 7
years old who received PCV as part of routine EPI or via the catch-up campaign,
recruited from households and public schools; (iii) randomly sampled healthy
children 3–10 years old who were age ineligible (born on or before 11 November
2010 and, therefore, too old to receive PCV as part of routine EPI or via the catch-
up campaign), recruited from households and public schools; and (iv) HIV-
infected adults 18–40 years old and on ART, recruited from Blantyre’s Queen
Elizabeth Central Hospital ART Clinic using systematic sampling. After evidence of
persistent carriage among children 3–10 years old during the early surveys,
recruitment of infants 4–8 weeks old and children 18 weeks to 2 years old was
implemented starting from survey 5 and survey 4, respectively. Exclusion criteria
for all participants included current tuberculosis treatment, pneumonia hospitali-
sation ≤14 days prior to screening, or terminal illness. Exclusion criteria for chil-
dren included parent/guardian not providing written informed consent, child 8–10
years old not providing written informed assent, reported immunocompromising
illness (including HIV), having received antibiotics ≤14 days prior to screening,
having received PCV if age ineligible or not having received PCV if age eligible.
Individuals were not purposely resampled but were eligible if randomly re-selected
in subsequent surveys.
Site selection and recruitment. Households, schools, and vaccination centres
were selected from within three non-administrative zones representative of urban
Blantyre’s socioeconomic spectrum in medium- to high-density townships. These
zones were further divided into clusters, allowing for ~25,000 adults per zone and
1200 adults per cluster. At the start of each rolling cross-sectional survey, eight
clusters were randomly selected. Clusters were not purposely resampled but eligible
if randomly selected in subsequent surveys. Within each cluster, after randomly
choosing a first house, teams moved systematically, recruiting one eligible child per
household until a required number of children were recruited from each cluster. If
no parent/guardian was available or no child age eligible for household recruitment
was at home (including when no one was home), the study team moved system-
atically to the next house without attempting to revisit the skipped household. At
the start of each survey, updated school registers were collected from schools.
Individual school-goers were randomly selected from school registers, and letters
were sent home inviting parents/guardians to travel to the school within the fol-
lowing 3 school days to discuss the study and consider consenting to their child’s
participation. If the parent/guardian did not respond to the letter or did not visit
the school within the specified 3 days, another child was randomly selected from
the school’s register.
Determining PCV vaccination status. A child was considered PCV vaccinated if
she/he had received at least one dose of PCV before screening. Vaccination status
and inclusion/exclusion criteria were further assessed from subject-held medical
records (known as health passports). If a child was reported by the parent/guardian
to be PCV vaccinated but no health passport was available, a questionnaire was
applied. The questionnaire was developed by identifying, among a subset of 60
participants, four questions most commonly answered correctly by parents/guar-
dians of children with proof of PCV vaccination. The questions included the child’s
age when vaccinated, vaccine administration route (oral or injectable), anatomical
site of vaccination, and which other (if any) vaccines were received at the time of
PCV vaccination. If the child was PCV age eligible and the parent/guardian
answered all four questions correctly, the child was recruited as PCV vaccinated.
Sample size. The sample size strategy was pragmatic to allow for adequate pre-
cision of the carriage prevalence estimates. VT carriage was considered the primary
endpoint, and the sample size was calculated based on the precision of the pre-
valence estimation, assuming an infinite sampling population. Among children 3–7
years old (vaccinated), an absolute VT prevalence up to 10% was expected, with a
sample of 300/survey providing a 95% CI of 6.6–13.4%. Among children 3–10 years
old (unvaccinated) and HIV-infected adults, an absolute VT prevalence of 20% was
expected, with a sample of 200/survey providing a 95% CI of 14.5–25.5%.
Nasopharyngeal swab collection. An NPS sample was collected from each par-
ticipant using a nylon flocked swab (FLOQSwabsTM, Copan Diagnostics, Murrieta,
CA, USA), and then immediately placed into 1.5 mL skim
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milk–tryptone–glucose–glycerol (STGG) medium and processed at the
Malawi–Liverpool–Wellcome (MLW) Trust laboratory in Blantyre, according to
WHO recommendations68. Samples were frozen on the same day at −80 °C.
Pneumococcal identification and latex serotyping. After being thawed and vor-
texed, 30 µL NPS–STGG was plated on gentamicin-sheep blood agar (SBG; 7% sheep
blood agar, 5 µL gentamicin/mL) and incubated overnight at 37 °C in 5% CO2. Plates
showing no S. pneumoniae growth were incubated overnight a second time before
being reported as negative. S. pneumoniae was identified by colony morphology and
optochin disc (Oxoid, Basingstoke, UK) susceptibility. The bile solubility test was used
on isolates with no or intermediate (zone diameter < 14mm) optochin susceptibility.
A single colony of confirmed pneumococcus was selected and grown on a new SBG
plate as before. Growth from this second plate was used for serotyping by latex
agglutination (ImmuLex™ 7-10-13-valent Pneumotest; Statens Serum Institute,
Denmark). This kit allows for differential identification of each PCV13 VT but not for
differential identification of NVT serotypes; NVT and non-typeable isolates were,
therefore, reported as NVT. Samples were batch tested on a weekly basis, blinded to
the sample source. Latex serotyping results showed good concordance with whole
genome sequence and DNA microarray serotyping69.
Statistical analysis. Participant demographic characteristics were summarised
using means, standard deviations, medians, and ranges for continuous variables
and frequency distributions for categorical variables. Non-ordinal categorical
variables were assessed as indicators. Comparison of covariate distribution between
study groups was done by independent group t-test for continuous covariates and
by chi-square (χ2) for categorical covariates. Potential confounders were identified
by testing the association between variables and VT carriage and included in the
multivariable models when p < 0.1. Carriage crude prevalence ratios and aPRs were
calculated over the study duration by log-binomial regression using years
(365.25 days) between Malawi’s introduction of PCV13 (12 November 2011) and
participant recruitment, coded as a single time variable. This allowed for an esti-
mated prevalence ratio per annum. Prevalence ratio analyses were restricted to
children 3–5 years old (PCV vaccinated), children 6–8 years old (PCV-unvacci-
nated) and adults. This (i) limited bias due to age, (ii) maximised the chance that
any change in carriage prevalence over time to be represented primarily by change
in calendar time (not ageing in time), and (iii) maximised the inclusion of age
category representatives with sequential years of the same PCV vaccination status.
The formula for relative change in carriage prevalence was: ([carriage prevalence of
final survey− carriage prevalence of initial survey]/carriage prevalence of initial
survey) × 100%. Confidence intervals are binomial exact. Statistical significance was
inferred from two-sided p < 0.05. Participant data collection was completed using
the Open Data Kit Collect open-source software. (v1.24.0). Statistical analyses were
completed using Stata 13.1 (StataCorp, College Station, TX, USA).
Non-linear regression analysis for VT carriage half-life. To better understand
the rate at which VT and NVT carriage prevalence was decreasing, we developed a
non-linear model to describe the variation in individual probability of VT or NVT
carriage with age, adjusted for age at recruitment. The model is fitted using carriage
data from children 3.6–10 years of age, maximising overlap with empirical data and
allowing direct comparisons of parameters between vaccinated and unvaccinated
children. Model outputs for individual VT and NVT carriage probability were then
transformed into a population-level (decay) half-life of each VT and NVT carriage
(i.e. time in years for VT and NVT carriage prevalence in the sampled cohort to
reduce to one-half of its peak), using log(2)/δ, where δ= rate of decay of VT or
NVT carriage prevalence with age. Model parameters were estimated by maximum
likelihood, and 95% confidence bands for the predicted exponential decay curves
are obtained through parametric bootstrap. This analysis used R open-source
software, version 3.5.0 (www.r-project.org). Details of the analysis framework are
included as Supplementary Note 1.
Consent to participate. Adult participants and parents/guardians of child parti-
cipants provided written informed consent, children 8-10 years old provided
informed assent. This included consent for publication.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data supporting the findings of this study have been deposited in the Figshare
repository (https://doi.org/10.6084/m9.figshare.11985255) (ref. 70). The source data
underlying Figs. 2 and 3 are available in the Supplementary Information, Supplementary
Tables 3 and 4, respectively. Figure 4 data are available with the coding data at: https://
github.com/claudiofronterre/pneumococco.
Code availability
The computer coding used to generate results in this manuscript is available at: https://
github.com/claudiofronterre/pneumococco.
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